Maarten van der Doelen

Chapter 2

11 Yes (8) Yes (1) No Yes Yes Yes (6) No No D-R-E-A-C

10 Yes (6) No No Yes Yes Yes (5) No No D-R-E-A

09 Yes (4) Yes (5) Yes (1) Yes Yes No No No D-A-C-E-CP

07 Yes (8+8) Yes (5) No Yes Yes Yes (6) No No D-A-K-A-D-E-C-R-A 08* Yes (6) No No No No No No No D

223 Radium dichloride 117 Lu-PSMA RLT Olaparib Sequence 01 Yes (7) No No Yes Yes Yes (6) No No A-D-R-E 02 Yes (8+8+7+8) Yes (8+9) No Yes Yes No No No D-D-D-A-D-E-C-A-C-E 03 Yes (10) Yes (9) No No No No No No D-C 04 Yes (7) No No Yes Yes No No No A-E-D-A 05 Yes (5) Yes (3) Yes (1) Yes Yes No No No A-E-D-C-A-CP 06 Yes (8) Yes (5) No Yes No No No No D-C-A

13 Yes (3+5) No No Yes Yes No Yes (2) No D-A-E-A-D-P

12 Yes (6) Yes (5+6) No Yes Yes No Yes (2) Yes O-E-D-C-C-OL-P-A

P = PSMA-Lu-177 radioligand therapy (cyles) R = Radium-223 (cyles) * Patient ID 08 showed rapid progressive disease after short response to LHRH plus upfront docetaxel. Immunohistochemistry of a metastatic biopsy revealed therapy induced neuroendocrine features. This patient was deemed to be resistant to androgen-receptor targeting agents. Therefore, 225 Ac-PSMA-617 TAT was initiated.

Supplementary table 1. Individual patient data on prior systemic therapies for metastatic prostate cancer. ID Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide

A = Abiraterone C = Cabazitaxel (cyles) CP = Carboplatin (cycles), combined with Cabazitaxel D = Docetaxel (cyles) E = Enzalutamide K = Ketoconazole O = Orteronel OL = Olaparib

46